EPO published patent EP3817762A1 for multifunctional protein molecules comprising decorin with therapeutic applications. The invention falls under multiple IPC classifications including A61K 38/16, A61K 38/17, A61K 38/20, A61K 38/21, A61K 38/39, A61K 39/395, A61K 47/42, and A61K 47/66, with specific therapeutic indications for cancer treatment under A61P 35/02 and A61P 35/04. The patent designates all 31 European Patent Convention contracting states covering the major European pharmaceutical markets.

Pharmaceutical companies and drug manufacturers should review this patent publication to assess potential freedom-to-operate implications for decorin-based therapeutic development programs. Patent applicants seeking European market protection for similar decorin protein technologies should consider filing divisional applications or pursuing alternative claim strategies. No immediate compliance action is required as patent publications do not create regulatory obligations.